Utility of clinical next generation sequencing tests in KIT/PDGFRA/SDH wild-type gastrointestinal stromal tumors

Most GISTs are driven by activating mutations in KIT and PDGFRA or alterations in the succinate dehydrogenase (SDH) complex, with the small fraction of GISTs lacking these alterations called “triple-negative” GISTs. Researchers assessed clinical genomic sequencing, treatment, and survival outcomes in a cohort of 20 triple-negative GISTs and observed limited benefit with imatinib. In-depth molecular profiling can be helpful in identifying driver mutations and guiding therapy.